Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 Drug-Drug Interaction Study with CYP3A4 Modulators
NCT05995249Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zasocitinib in psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 16, Area Under the Curve from Time 0 to Infinity at Day 16 and 1 more. Started Aug 2023; status: completed.
02
Drugs
zasocitinib
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05995249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995249.